Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient’s and caregiver’s quality of life because of its oral...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. Varghese
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-03-01
Serie:	Frontiers in Pediatrics
Soggetti:	pediatric pulmonary hypertension selexipag treprostinil initiation transition prostacyclin
Accesso online:	https://www.frontiersin.org/articles/10.3389/fped.2023.1050508/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!